Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis.
RMD open(2023)
Abstract
The results of this integrated safety analysis in patients with SLE are not substantially different to the established safety profile of baricitinib. No increased venous thromboembolism was found.
MoreTranslated text
Key words
baricitinib,systemic lupus erythematosus
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined